ICI Users Have Significant Decline in Psoas Muscle Density - Oncology Nurse Advisor Researchers explored the effect of immune checkpoint inhibitors on psoas muscle density and skeletal muscle index in patients with melanoma.

#PsoasMuscleDensity declined more in patients receiving ICIs.

https://bit.ly/4rtsQIO

#skcsm

The ORR was 28.2% for younger patients and 30.4% for older patients, and the DCR was 43.9% and 48.8%, respectively.

https://bit.ly/4smejPS

#melanoma #melsm #skcsm

The RFS benefit of adjuvant pembrolizumab given for high-risk stage II #melanoma persists even after accounting for new melanoma diagnoses. Published in @jamanetworkopen.com.

https://bit.ly/4kUR9xH

#melcsm #skcsm

14% of adults under 35 believe sunscreen is riskier than UV exposure. Clinical intervention is required to counter this trend.

☀️ SPF 15+ reduces melanoma risk by 50% ☀️ UV is a proven human carcinogen

Read the review: https://bit.ly/46g3OF9

#skcsm #melcsm #nosunscreen

Anticoagulation Therapies May Improve Survival in Advanced BRAF-Mutant Melanoma - Oncology Nurse Advisor Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV BRAF-mutant melanoma.

Patients with advanced #melanoma who received anticoagulation therapy, particularly direct oral anticoagulants (DOACs), saw improvements in survival. Published in @cancertherapyadv.bsky.social.

https://bit.ly/469nAlL

#melcsm #skcsm

Non-Melanoma Skin Cancer More Common in Gay and Lesbian Individuals Researchers investigated non-melanoma skin cancer prevalence among sexual orientation identities by race/ethnicity and gender.

Non-melanoma #skincancer is more common in gay and lesbian individuals than in heterosexual individuals. Published in @aacrjournals.bsky.social journal Cancer Epidemiology, Biomarkers & Prevention.

https://bit.ly/4pg96HT

#skcsm #LGBTOnc

AI-Detected Tumor-Infiltrating Lymphocytes Associated with ICI Response in Melanoma “These findings support the potential of AI-driven histopathological analysis as a biomarker in melanoma,” study researchers wrote.

In #melanoma patients, the presence of tumor-infiltrating lymphocytes in pretreatment samples, detected using an AI-based tool, is associated with outcomes with ICI therapy. Published in @jamaoncology.com.

https://bit.ly/43uCx0C

#melsm #skcsm

Rule Out Melanoma Terminology on Pathology Requisitions Has Low Predictive Value - Oncology Nurse Advisor Researchers studied the diagnostic yield associated with rule of melanoma terminology used on skin biopsy requisition forms.

The use of rule out #melanoma terminology on pathology requisitions has a low positive predictive value for the diagnosis of melanoma. Published in @dermatologyadvisor.bsky.social.

https://bit.ly/4oHtCRr

#melcsm #skcsm

Adjuvant cemiplimab may reduce the risk of second primary tumors in patients with high-risk cutaneous squamous cell carcinoma, data suggest. Presented at #ESMO25 by Dr Danny Rischin of @petermaccc.bsky.social. #skcsm

shorturl.at/dZdi8

Therapeutic plasma exchange may allow patients with advanced melanoma to overcome immune checkpoint inhibitor resistance, according to research presented at #ESMO25 by Dr Jacob Orme of @mayocliniccancer.bsky.social. #melsm #skcsm #ESMO25

shorturl.at/t5NSs

The combination of pembrolizumab and EVX-01, a personalized peptide-based neoantigen cancer vaccine, has shown durable activity in patients with advanced melanoma, according to research presented #ESMO25 by Dr Adnan Khattak. #melsm #skcsm #esmo2025

shorturl.at/Yl08y

Systemic Therapy More Effective for Some Rare Skin Cancers Than Others “Type and outcome of systemic therapy differed between cancer entities,” the researchers wrote.

The efficacy of systemic therapy varies among patients with rare #skincancers, but patients with cutaneous adnexal carcinoma have poor outcomes regardless of the therapy they receive.

https://bit.ly/42yPlT2

#skcsm

Systemic Therapy More Effective for Some Rare Skin Cancers Than Others “Type and outcome of systemic therapy differed between cancer entities,” the researchers wrote.

The efficacy of systemic therapy varies among patients with rare skin cancers, but patients with cutaneous adnexal carcinoma have poor outcomes regardless of the therapy they receive, researchers report. shorturl.at/4cBde #skcsm

Adding Lenvatinib to Pembrolizumab Provides No Benefit in Unresectable Melanoma “Immunotherapy remains the standard of care for the first-line treatment of advanced melanoma,” the researchers wrote.

Adding lenvatinib to treatment with pembrolizumab does not improve outcomes in patients with unresectable, advanced melanoma who have not received prior treatment with PD-(L)1 inhibitors, research suggests. shorturl.at/4fVxp #skcsm #melsm

Cancer Vaccine Candidate Narrowly Misses Endpoint in Advanced Melanoma Trial - Oncology Nurse Advisor Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 positive cells.

Topline results were announced from a phase 3 trial evaluating Cylembio® (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced #melanoma. From @medicalprofref.bsky.social.

https://bit.ly/4g34JMY

#melsm #skcsm

High Sucralose Intake May Reduce Efficacy of ICIs “Future prospective studies will be necessary to assess potential causation of sucralose in driving immunotherapy resistance as well as to determine how other demographic factors, including location a...

High intake of the artificial sweetener sucralose may reduce the efficacy of immune checkpoint inhibitors in cancer patients, according to research published in @aacrjournals.bsky.social. shorturl.at/U9TvO #lcsm #skcsm #melsm #OncSky

The site of metastasis is associated with outcomes of IO, surgery, and IO + surgery in advanced melanoma, according to research published in JAMA Surgery. #skcsm #melsm www.cancertherapyadvisor.com/news/melanom...

C-IT Neo: interim results of neoadjuvant ipilimumab & nivolumab in melanoma - VJOncology Sarah Lochrin, MBBCh, Memorial Sloan Kettering Cancer Center, New York, NY, discusses interim results from the Phase II C-IT Neo...

🎥Sarah Lochrin of @mskcancercenter.bsky.social shares interim Phase II C-IT Neo trial results

Watch ➡️https://buff.ly/DawY2Ju

#ASCO25 #Melsm #Skcsm #CTSM #TrialUpdate #ImmunoOnc

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma, according to research presented at #ASCO25. #skcsm #melsm shorturl.at/QpS8W

High-Fiber Diet May Improve Response to Immunotherapy A high-fiber diet may improve response rates and event-free survival outcomes in patients with advanced melanoma receiving standard immunotherapy.

In study results presented at #ASCO25 by Yufan Qiu, MD, PhD, of @mdanderson.bsky.social, a high-fiber diet improved response rates and EFS in patients with advanced melanoma receiving standard immunotherapy. shorturl.at/JxDbq #melsm #skcsm

Radionuclide Therapy Appears Safe, Effective for Non-Melanoma Skin Cancer Rhenium-SCT is an epidermal radionuclide therapy that utilizes a radioisotope-based resin to treat shallow non-melanoma skin cancer lesions.

A radionuclide treatment for non-melanoma skin #cancer is well tolerated and effective in patients with shallow skin lesions, researchers report. shorturl.at/QlovL #skcsm

Cross-resistance between targeted therapies and immune checkpoint inhibitors in melanoma - VJOncology Grant McArthur, MBBS, FRACP, PhD, FAHMS, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the importance of understanding the interaction between...

🎥Prof. Grant McArthur from Peter Mac (@petermaccc.bsky.social) highlights how targeted therapy reshapes the immune microenvironment in melanoma, impacting response to IO. Smarter sequencing is key!

Learn more here➡️https://buff.ly/huymybh

#Melanoma2025 #EADO2025 #Melsm #Skcsm #ImmunoOnc

Japanese and East Asia-specific guidelines for the management of melanoma - VJOncology Satoshi Fukushima, MD, PhD, Kumamoto University, Kumamoto, Japan, discusses differences in melanoma subtype and drug efficacy between Western countries and...

🎥Prof. Satoshi Fukushima highlights the need for region-specific melanoma guidelines—Japanese data show PD-1 monotherapy may outperform dual IO for BRAF WT melanoma:

➡️https://buff.ly/CdL2xV9⬅️

#Melanoma2025 #EADO2025 #melsm #skcsm #ImmunoOnc

Potential of ADCs in treating melanoma - VJOncology Georgina Long, PhD, MBBS, FRACP, FAHMS, University of Sydney, North Sydney, Australia, reflects on the potential of antibody-drug conjugates (ADCs)...

🎥Professor Georgina V Long (@gvlongphdmd.bsky.social) highlights the promise of antibody-drug conjugates (ADCs) in melanoma but stresses payload choice & durability as key challenges:

➡️https://buff.ly/pn2alez⬅️

#Melanoma2025 #EADO2025 #ImmunoOnc #MelSM #Skcsm

40-GEP Test Can Improve Risk Stratification in CSCC A 40-gene expression profile test can improve risk stratification for patients with CSCC, according to researchers.

A 40-GEP test can improve risk stratification for patients with CSCC, according to research presented at #NCCN2025 by Dr Shlomo Koyfman of @clevelandclinic.bsky.social. #skcsm shorturl.at/78Vpj

Tilsotolimod Provides No Added Benefit in Advanced Melanoma “Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this...

The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced #melanoma. Published by @ascocancer.bsky.social.

bit.ly/4bvDw3r

#skcsm #melsm

Skin Cancer Sessions: PD-1 refractory skin cancer

Missed our #SkinCancer Session?

Worry not, as you can watch @drbetofmdphd.bsky.social, Omid Hamid & Inderjit Mehmi discuss therapeutic options for PD-1 refractory skin cancer on demand!!

Watch here 👉 www.vjoncology.com/event/skin-c... 👈

#Oncology #Melsm #Skcsm #melanoma